Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate

Purpose: Epidermal growth factor receptor (EGFR) is overexpressed in approximately 50% of invasive breast carcinomas and it is correlated with hormone resistance and poor prognosis. EGFR suppression by gefitinib, a quinazoline derivative that inhibits phosphorylation of the specific receptor, repres...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2005-12, Vol.16 (12), p.1867-1873
Hauptverfasser:	Gasparini, G., Sarmiento, R., Amici, S., Longo, R., Gattuso, D., Zancan, M., Gion, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences breast cancer Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - secondary Dose-Response Relationship, Drug epirubicin Epirubicin - administration & dosage ErbB Receptors - blood Female Gefitinib Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Maximum Tolerated Dose Medical sciences Middle Aged Neoplasm Invasiveness Pharmacology. Drug treatments phase I study Quinazolines - administration & dosage Receptor, ErbB-2 - blood Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!